STAAR Surgical Co. achieved a remarkable $93.5 million in net sales for the second quarter, marking a 111% year-over-year increase. This growth indicates a strong Demand for its EVO ICLs and reflects the company's effective market strategies, positioning it favorably for future performance.
Key Highlights
- Second-quarter Revenue increased 111% year-over-year, driven by strong demand from China.
- Adjusted EBITDA for Q2 reached $20.0 million, with adjusted EPS of $0.39 per diluted share.
- The second-quarter financial results paint a positive picture, with net sales soaring to $93.5 million.
STAAR Surgical Co. (NASDAQ: STAA), a leading provider in the medical specialties industry, reported an exceptional second quarter performance, achieving net sales of $93.5 million, which represents a stunning 111% increase compared to the previous year. This surge in revenue showcases the effectiveness of STAAR's focus on its Implantable Collamer® Lens (EVO ICL) offerings, particularly within its largest market, China. The company's market Capitalization stands at approximately $1.1 billion, reflecting sustained investor interest and confidence in its growth strategy.
The results outperformed expectations, as the consensus estimate for Earnings Per Share (EPS) was set at $0.16, but STAAR delivered a strong $0.31 EPS for the quarter ending June 30, highlighting the company's successful execution in a competitive marketplace. Such growth positions STAAR competitively amongst its sector peers, with momentum expected to continue as demand for its products aligns well with market trends.
Revenue Expansion Drives Results
The second-quarter financial results paint a positive picture, with net sales soaring to $93.5 million. This growth was bolstered by an astonishing 100% increase in sales within China, where the company generated $52.3 million. Revenue outside of China hit $41.2 million, reflecting a solid 6.0% year-over-year increase.
The substantial demand for EVO ICL procedures has propelled STAAR to capture a significant market share, especially given that over half of the company's revenue now derives from the Chinese market. This explosive growth trend is underscored by STAAR's investments in product innovation and market education, which have proved vital in enhancing their competitive edge. Continued success in this domain will be critical for sustaining revenue growth in future quarters.
Profitability and Operating Leverages Enhance Performance
The improved profitability is evident as the company’s adjusted EBITDA surged to $20.0 million, reflecting more efficient operational practices. The gross Margin expanded slightly to 74.5%, indicating that while revenue is growing robustly, the company's cost management strategies are also working effectively. Investing in efficiency improvements and production capabilities has allowed STAAR to Capitalize on revenue growth while optimizing profit margins.
As market conditions remain favorable, maintaining this Operating Leverage will be paramount for sustaining profitability amidst potential fluctuations in demand.
Strong Demand Signals Future Growth
The current sales dynamics in key regions, especially China, highlight STAAR’s capability to capture growth opportunities. The company's significant share in the growing lens-based refractive surgery market, alongside a strategic shift toward higher-value toric lenses, positions STAAR for ongoing success. The anticipated continuation of demand through the remainder of the fiscal year further solidifies the outlook, suggesting that the trends witnessed in Q2 may persist.
Given the forthcoming Earnings Call on August 12, 2026, further insights into STAAR’s strategic priorities and performance expectations will be important for investors looking to gauge long-term viability.
Technical Performance Insights
The stock is maintaining a position above several key moving averages, showing relative strength despite a recent dip over the past month. The stock trades above its 20-day Moving Average of $24.41 and its 200-day average of $24.28 but below its 50-day average of $26.97, indicating a mixed technical picture. The 14-day RSI stands at 51.0, suggesting neutral momentum, while the MACD is currently at -0.68, indicating that the stock is exerting some upward pressure.
Next critical resistance levels are identified at $29.12 and $33.88, while support levels stand at $20.40 and $16.44, which may play a key role in future price movements.
Peers Moving on This News
- QuidelOrtho Corp (NASDAQ: QDEL) little changed
- Bioventus Inc (NASDAQ: BVS) little changed
- OrthoPediatrics Corp (NASDAQ: KIDS) little changed



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...